Emerging technologies for protease engineering: New tools to clear out disease
- 17 August 2016
- journal article
- review article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 114 (1) , 33-38
Abstract
Proteases regulate many biological processes through their ability to activate or inactive their target substrates. Because proteases catalytically turnover proteins and peptides, they present unique opportunities for use in biotechnological and therapeutic applications. However, many proteases are capable of cleaving multiple physiological substrates. Therefore their activity, expression, and localization are tightly controlled to prevent unwanted proteolysis. Currently, the use of protease therapeutics has been limited to a handful of proteases with narrow substrate specificities, which naturally limits their toxicity. Wider application of proteases is contingent upon the development of methods for engineering protease selectivity, activity, and stability. Recent advances in the development of high‐throughput, bacterial and yeast‐based methods for protease redesign have yielded protease variants with novel specificities, reduced toxicity, and increased resistance to inhibitors. Here, we highlight new tools for protease engineering, including methods suitable for the redesign of human secreted proteases, and future opportunities to exploit the catalytic activity of proteases for therapeutic benefit. Biotechnol. Bioeng. 2017;114: 33–38.Keywords
Funding Information
- National Science Foundation Graduate Research Fellowship (DGE-1144085)
This publication has 34 references indexed in Scilit:
- Simultaneous selection and counter‐selection for the directed evolution of proteases in E. coli using a cytoplasmic anchoring strategyBiotechnology and Bioengineering, 2015
- A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutationsNature Communications, 2014
- Quantitative assessment of in vivo HIV protease activity using genetically engineered QD‐based FRET probesBiotechnology and Bioengineering, 2014
- A system for the continuous directed evolution of biomoleculesNature, 2011
- Proteases as therapeuticsBiochemical Journal, 2011
- Thrombin as procoagulant and anticoagulantJournal of Thrombosis and Haemostasis, 2007
- Coagulation cascade proteases and tissue fibrosisBiochemical Society Transactions, 2002
- Matrix Metalloproteinase Inhibitors and Cancer—Trials and TribulationsScience, 2002
- Amyloid Fibril Formation by Aβ16-22, a Seven-Residue Fragment of the Alzheimer's β-Amyloid Peptide, and Structural Characterization by Solid State NMRBiochemistry, 2000
- The plasminogen activation system in tumor growth, invasion, and metastasisCellular and Molecular Life Sciences, 2000